SCHEMBL3428485

SCHEMBL3428485

C=CCc1ccc(Nc2cc(Nc3ccc(CC=C)cc3)cc(Nc3ccc(CC=C)cc3)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
CYP3A4 P08684 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALOX15 P16050 2/20 0.45
TSHR P16473 2/20 0.45
ALOX12 P18054 2/20 0.45
XDH P47989 1/20 0.45
TP53 P04637 1/20 0.45
MAPT P10636 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
GABRA1 P14867 4/20 0.44
GABRB2 P47870 4/20 0.44
GAA P10253 3/20 0.44
CNR2 P34972 3/20 0.44
PPARG P37231 2/20 0.44
PPARD Q03181 2/20 0.44
CNR1 P21554 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH2 P05091 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6406231 0.93 ALDH1A1 (0.50) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL175889 0.93 ALDH1A1 (0.50) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL2582312 0.85 ALDH1A1 (0.54) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL28999966 0.83 ALDH1A1 (0.48) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL4614917 0.83 MEN1 (0.44) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL1173026 0.80 ALDH1A1 (0.59) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL11138322 0.79 CYP3A4 (0.58) ALDH1A1CYP3A4ALOX15TSHRALOX12
Diphenylamine SCHEMBL7578440 0.78 HSD17B10 (0.52) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL173301 0.78 ALDH1A1 (0.64) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR
SCHEMBL24292261 0.76 ALDH1A1 (0.46) ALDH1A1CYP3A4SMN1; SMN2ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496044-B1 NOVEL 1,3,5-TRIS(ARYLAMINO)BENZENE BANDO CHEMICAL IND (JP) 2010-11-03 EP disclosed
US-7196224-B2 1,3,5-tris(arylamino)benzenes BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2007-03-27 US disclosed
US-20050090692-A1 Novel 1,3,5-tris(arylamino)benzene BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2005-04-28 US disclosed
EP-1496044-A1 NOVEL 1,3,5-TRIS(ARYLAMINO)BENZENE Bando Chemical Industries, Ltd. (JP) 2005-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090692-A1 Novel 1,3,5-tris(arylamino)benzene AHR, MYB, NAP1L4 ALDH1A1 727/4885CYP3A4 64/4885SMN1; SMN2 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.